Cassava Sciences, Inc. (SAVA)
NASDAQ: SAVA · Real-Time Price · USD
2.030
-0.010 (-0.49%)
At close: Mar 6, 2026, 4:00 PM EST
2.013
-0.017 (-0.86%)
After-hours: Mar 6, 2026, 7:40 PM EST
Cassava Sciences Employees
Cassava Sciences had 30 employees as of December 31, 2024. The number of employees increased by 1 or 3.45% compared to the previous year.
Employees
30
Change (1Y)
1
Growth (1Y)
3.45%
Revenue / Employee
n/a
Profits / Employee
-$3,534,367
Market Cap
98.07M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Agenus | 316 |
| Seer, Inc. | 134 |
| Korro Bio | 87 |
| Precision BioSciences | 67 |
| Equillium | 35 |
| Oncolytics Biotech | 28 |
| Gain Therapeutics | 25 |
| TuHURA Biosciences | 19 |
SAVA News
- 16 days ago - Cassava Sciences says US DOJ has closed investigation into company - Reuters
- 2 months ago - HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PRNewsWire
- 2 months ago - FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold - Benzinga
- 4 months ago - Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 4 months ago - Cassava Sciences Appoints Dawn C. Bir to the Board of Directors - GlobeNewsWire
- 7 months ago - Cassava Reports Q2 2025 Financials Results and Provides Business Update - GlobeNewsWire
- 7 months ago - Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer - GlobeNewsWire
- 7 months ago - Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy - GlobeNewsWire